Medicare Covers Weight Loss Drugs at $50 Starting July

Starting July 1, Medicare patients struggling with obesity will finally get affordable access to breakthrough weight loss medications that once cost hundreds of dollars each month.

The new Medicare GLP-1 Bridge program offers popular weight loss drugs like Wegovy, Zepbound, and Foundayo for a flat $50 monthly copay. Before this program, many patients paid around $350 a month out of pocket, putting these life-changing medications out of reach for millions of seniors.

This marks a historic shift. For the first time ever, Medicare will help cover drugs prescribed specifically for weight loss, not just for related conditions like diabetes or heart disease.

The federal government designed the program using existing legal authority to create temporary initiatives. It runs through December 2027, giving roughly 3.8 million Medicare beneficiaries a chance to access medications that can significantly improve their health.

To qualify, patients need Medicare Part D coverage and must meet specific health criteria. That means having a BMI of at least 35, or a lower BMI combined with conditions like heart failure, uncontrolled high blood pressure, prediabetes, or history of heart attack or stroke.

Doctors will need to submit prior authorization showing their patient meets these requirements. The process ensures medications reach people who need them most while the program tests broader Medicare coverage.

The Ripple Effect

This pilot program could reshape how America treats obesity in older adults. By making these medications affordable, Medicare is acknowledging obesity as a serious health condition worthy of treatment, not just a lifestyle choice.

The savings go beyond the monthly copay. Better weight management often leads to improved outcomes for heart disease, diabetes, and other costly conditions. Healthier seniors mean fewer emergency room visits and hospital stays down the road.

The program also puts pressure on drug manufacturers to maintain lower prices after 2027. With millions of patients accessing $50 medications through the bridge program, companies may struggle to justify charging seven times more once the pilot ends.

Health policy experts see this as a testing ground for permanent coverage. If the program shows positive health outcomes and manageable costs, Congress could make Medicare coverage for weight loss drugs permanent.

Patients interested in the program should talk with their doctors now about eligibility. With coverage starting this summer, millions of Medicare beneficiaries have a real path to medications that were financially impossible just months ago.